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Background: The p53 pathway is differentially activated in response to distinct DNA damage, leading to alternative
phenotypic outcomes in mammalian cells. Recent evidence suggests that p53 expression dynamics play an
important role in the differential regulation of cell fate, but questions remain as to how p53 dynamics and the
subsequent cellular response are modulated by variable DNA damage.
Results: We identified a novel, bimodal switch of p53 dynamics modulated by DNA-damage strength that is crucial
for cell-fate control. After low DNA damage, p53 underwent periodic pulsing and cells entered cell-cycle arrest.
After high DNA damage, p53 underwent a strong monotonic increase and cells activated apoptosis. We found that
the damage dose-dependent bimodal switch was due to differential Mdm2 upregulation, which controlled the
alternative cell fates mainly by modulating the induction level and pro-apoptotic activities of p53.
Conclusions: Our findings not only uncover a new mode of regulation for p53 dynamics and cell fate, but also
suggest that p53 oscillation may function as a suppressor, maintaining a low level of p53 induction and pro-apoptotic
activities so as to render cell-cycle arrest that allows damage repair.Background
An efficient and precisely controlled DNA-damage re-
sponse is crucial for cell survival. In mammalian cells,
the p53 regulatory pathway, consisting mainly of the
tumor suppressor protein p53 and its downstream tran-
scriptional targets, plays an essential role in mediating
this crucial stress response to chromosomal damage
[1-3]. Depending on the type and severity of DNA dam-
age, the p53 pathway activates either cell-cycle arrest
that allows repair of the damage or alternatively, death
of the cell through apoptosis, but the mechanism by
which variation in DNA-damage strength differentially
regulates p53 pathway dynamics, and the effect that this
has on cell fate, are poorly understood.
Mild DNA damage generally induces a moderate in-
crease in p53 level, and results in transient cell-cycle ar-
rest that allows damage repair, whereas severe and
possibly irreparable DNA damage leads to a large in-
crease in p53, followed by cell death [4]. DNA damage is* Correspondence: qi@pku.edu.cn; jshi@hkbu.edu.hk
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reproduction in any medium, provided the orknown to upregulate p53 by attenuating its interaction
with Mdm2, the E3 ubiquitin ligase that targets p53 for
proteasome-mediated degradation [5,6]. Less clear is
how the severity of DNA damage modulates the degree
of attenuation in p53-Mdm2 interactions, giving rise to
differential p53 expression that results in these alterna-
tive cell fates. Also not clear is how the dynamics of p53
differ with variation in damage level, and what role any
changes in the dynamics might play in the downstream
function of p53. Most previous studies of p53 dynamics
have focused only on the response to transient DNA
damage induced by gamma or UV irradiation, which has
been shown to induce an intriguing oscillatory behavior of
p53, which is largely independent of DNA damage level
[7-11]. Moreover, although recent results, including our
own [11,12], have shown that p53 dynamics can be altered
by using nutlin to inhibit Mdm2, the observed change in
p53 dynamics was again independent of damage severity.
To investigate whether and how DNA-damage strength
modulates p53 dynamics and subsequently alters cell-fate
outcome, we performed a dose–response study by meas-
uring the real-time p53 dynamics under variable DNA
damage generated by etoposide, a chemotherapeutic com-
pound that induces sustained DNA damage. Using time-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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single-cell level, and correlated the dynamics with cell
fates. Our results showed that p53 dynamics exhibit
‘switch-like’ behavior, changing from oscillatory dynamics
at low damage to monotonic increase at high damage.
Moreover, this damage dose-dependent, bimodal switch of
p53 dynamics was found to regulate cell fate mainly by
modulating the p53 induction level and its pro-apoptotic
activities as a function of DNA-damage strength. Our re-
sults suggest that under certain conditions, p53 oscilla-
tions may act as a mechanism to suppress p53 induction,
thereby restraining its pro-apoptotic activities and pro-
moting cell-cycle arrest that allows DNA-damage repair.
Results
Dynamics of nuclear p53 is damage dose-dependent
To obtain data on p53 dynamics and cell fate as a func-
tion of DNA-damage strength, we performed dose titra-
tion of a DNA-damaging drug, etoposide, on U-2 OS
cells expressing a fluorescent p53 reporter. The reporter
cell line was generated by infecting U-2 OS cells with
lentivirus encoding an established wild-type p53-Venus
reporter construct [9]. For the study, we selected an iso-
genic clone that exhibited behaviors most similar to the
parental line (refer to discussion below). We used
etoposide as the DNA-damage stimulus, as it is known to
trigger DNA double-strand breaks (DSBs) by inhibiting
topoisomerase II [13,14]. To select the appropriate range
of etoposide dosage for activating variable amounts of
DNA damage, we first measured the level of DNA damage
under different etoposide doses. DNA damage, as indi-
cated by the DNA-damage marker, phospho-H2A.X, was
present after 12 hours of drug treatment (Figure 1a), andFigure 1 Differential p53 dynamics as a function of DNA-damage stre
treated with increasing doses of etoposide for 12 hours. Actin served as a l
p53 in the clonal U-2 OS report line treated with 1 and 100 μmol/l etoposi
(around 80 kDa) and the lower band is endogenous p53 (approximately 53
quantified from p53-Venus fluorescence. U-2 OS cells were treated with eithe
Individual cells were tracked for 72 hours or until cell death occurred. The abr
of death.the degree of DNA damage increased with increasing dos-
age of etoposide from 1 μmol/l to 75 to 100 μmol/l.
To verify that dynamics of the p53-Venus reporter
construct in our clonal reporter line mimicked the en-
dogenous p53, we compared the dynamics of the en-
dogenous and fluorescently tagged p53 by western
blotting. The dynamics of the p53-Venus construct that
we used have been extensively studied previously in
MCF7 cells, which all showed that the reporter con-
struct behaved similarly to the endogenous p53 [9,10].
Our data from the U-2 OS clone also showed similar
induction dynamics between p53-Venus and its en-
dogenous counterpart (Figure 1b; note that the level of
p53-Venus reporter is about half of the endogenous p53.
For quantified results of western blots, see Additional
file 1: Figure S1), when cells were treated with both low
and high doses of etoposide. Therefore, the fluorescent
p53 reporter is probably regulated similarly to the en-
dogenous wild-type p53, and can be used to infer p53
dynamics in response to DNA damage.
From time-lapse microscopy movies, we quantified the
real-time induction dynamics of p53 by measuring aver-
age Venus fluorescence in the nucleus and cytoplasm,
respectively. In general, the fluorescent signal of p53-
Venus in the nucleus was significantly higher than that
in the cytoplasm. Single-cell p53 fluorescence trajector-
ies showed two distinctive dynamic features: 1) nuclear
p53 exhibited periodic pulsing at low drug dose, but
monotonic increase at high dose; and 2) the amplitude of
monotonically elevated p53 was substantially higher than
that of the pulsing mode (Figure 1c; see Additional file 1:
Figure S2). These bimodal, damage dose-dependent p53
dynamics are in stark contrast to the dose-independentngth. (a) Phospho-H2A.X levels (DNA damage marker) in U-2 OS cells
oading control. (b) Induction kinetics of p53-Venus and endogenous
de at the indicated time points (in hour). The upper band is p53-Venus
kDa). (c) Single-cell trajectories of p53 dynamics at the nucleus
r 1 μmol/l (black lines) or 100 μmol/l (red lines) of etoposide at time 0.
upt end of p53 trajectories before 72 hours corresponds to the time
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ously identified in single mammalian cells [8]. The obser-
vation of a switch from oscillatory dynamics to a
monotonic increase in p53 as DNA damage increased also
suggests an intriguing new transitional regulation of p53.
The distinct mode of p53 dynamics strongly correlates
with cell fate
Besides p53 dynamics, cumulative survival curves (quan-
tified by analyzing individual cell fate from the time-
lapse movies) showed that cell fate was also altered. As
the dose of etoposide increased from 1 to 100 μmol/l,
the cell-fate profile shifted from primarily cell-cycle ar-
rest (scored by absence of cell division in 72 hours) to
primarily cell death, with 100 μmol/l being the saturat-
ing dose for the cell-death response (Figure 2a). The
dose response of the U-2 OS p53 reporter line was simi-
lar to that of the parental line, with the reporter line be-
ing slightly more sensitive to etoposide, probably due to
the extra copies of p53 (see Additional file 1: Figure S3).
Moreover, the single-cell data from the reporter line
showed that the phenotypic outcome of arrest versus
death correlated strongly with the dynamic mode of p53,
as overall 86% of the cells (summed over all drug
concentrations) that showed p53 pulsing went into cell-
cycle arrest, and more than 96% of those with monotonic
p53 induction died. Figure 2b shows the distributions of
the four observed response phenotypes at different
etoposide doses: 1) pulsing p53 followed by cell-cycle
arrest, 2) pulsing p53 followed by cell death, 3) monotonic
increase of p53 followed by cell-cycle arrest, and 4) mono-
tonic increase of p53 followed by cell death. At all
etoposide doses, phenotypes 1 and 4 accounted for more
than 85% of the cells seen. In particular, at low DNA dam-
age (etoposide ≤5 μmol/l), more than 65% of cells showed
periodic pulsing and cell-cycle arrest, whereas at high
DNA damage (etoposide ≥80 μmol/l) more than 95% cells
died after monotonic elevation of p53.
To determine whether other mammalian cells exhibit
a bimodal switch of p53 dynamics that correlates with
cell fate as a function of DNA-damage strength, we gen-
erated another clonal fluorescent p53 reporter cell line
in A549 cells. Dose titration results of the A549-p53 re-
porter line showed that A549 was more resistant than
U-2 OS to etoposide, requiring higher concentrations to
induce both cell-cycle arrest (5 μmol/l) and cell death
(150 μmol/l) to near saturation level (see Additional file 1:
Figure S4). In A549 cells, p53 again showed a bimodal
switch of dynamics similar to that observed in U-2 OS
cells, namely, pulsing at low DNA damage and monotonic
increase at high DNA damage (Figure 2c). The strong
correlation between cell fate and the two distinct p53
dynamic modes was also seen in A549 cells (Figure 2d).
Overall, 97% of A549 cells that displayed p53 pulsing wentinto cell-cycle arrest, and more than 83% of those with
monotonic p53 induction died. Our data thus suggest that
the bimodal switch and its correlation with alternative cell
fate are common in at least some mammalian cells in re-
sponse to variable DNA damage.
We noted that although the correlation between cell
fate and p53 induction dynamics was evident across the
entire cell population, there was strong cell-to-cell vari-
ation in terms of the quantitative characteristics. We
quantified the single-cell data and population average for
the two p53 dynamic modes observed in U-2 OS cells at
different etoposide concentrations (Figure 2e). For the
pulsing mode, the pulsing period of the initial two to five
pulses varied between individual cells from approxi-
mately 6 to approximately 40 hours, and the pulsing
amplitude spanned a nearly eight-fold range. Further-
more, more than 50% of cells displayed irregular oscilla-
tory behaviors with change in either pulsing period or
amplitude over time. The strong single-cell variability
was also evident for the monotonic induction mode, as
shown by the large standard deviations in the population
averages in terms of both the rate of p53 increase and
the maximal p53 level (Figure 2e). In addition, our re-
sults appeared to show distinct dose dependence of the
two p53 dynamic modes. Both the average pulsing
period and the pulsing amplitude exhibited a moderate
increase as the etoposide concentration increased,
whereas the rate of increase and the maximal p53 level
under the monotonic induction mode was largely dose-
independent.
Mdm2 expression level controls the dynamic mode of
p53 induction
p53 level is known to be negatively regulated by the E3
ubiquitin ligase Mdm2, while at the same time Mdm2 is
transcriptionally activated by p53. Such a negative feed-
back loop between p53 and Mdm2 maintains p53 at a
low level in unstressed cells. Upon induction of DNA
damage, the inhibitory interaction between p53 and
Mdm2 is disrupted by phosphorylation of both proteins,
resulting in p53 accumulation [15]. To test whether the
bimodal switch of p53 induction is a result of differences
in Mdm2 activation, we performed immunoblotting to
compare the dynamics of ensemble p53 and Mdm2 at 1
and 100 μmol/l etoposide, as under these two extreme
concentrations, cells largely exhibited the same p53 dy-
namics of either pulsing or monotonic increase. The
level of p53 increase was substantially higher at high
drug dose than low dose for U-2 OS cells (Figure 3),
agreeing with the live-cell imaging observations. Intri-
guingly, whereas expression of Mdm2 steadily increased at
1 μmol/l etoposide, its expression was largely suppressed
at 100 μmol/l. Our data thus indicate that attenuation in
upregulation of Mdm2 at high DNA damage may enable
Figure 2 (See legend on next page.)
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Figure 2 Bimodal switch of p53 dynamics and its correlation with cell-fate outcome. (a) Cumulative survival curves for U-2 OS cells treated
with etoposide at the indicated dose from 1 to 150 μmol/l. The total number of cells analyzed for each curve ranged from 77 to 113, and varied
between conditions. Individual cells were monitored by phase-contrast and fluorescence time-lapse microscopy from drug addition for 72 hours
or until morphological death occurred. Kinetics of cell death were plotted as cumulative survival curves. (b) Distribution of the four response
phenotypes with respect to p53 dynamics and cell fate (as discussed in the text) to DNA damage triggered by etoposide at the indicated doses.
Error bars show standard deviations (SDs) of data from two independent experiments. (c) Single-cell trajectories of p53 dynamics at the nucleus
quantified from the A549-p53 reporter line. (d) Distribution of the four response phenotypes in A549 cells at the indicated etoposide doses. The
total number of cells analyzed for each concentration ranged from 81 to 106. Error bars show SDs of data from two independent experiments.
(e) Characteristics of the two p53 dynamic modes in individual cells (denoted by the black dots) and the population average (denoted by the red
bars). (Left) pulsing period and pulsing amplitude; (right) rate of monotonic increase and maximum amplitude. Thirty cells were analyzed for each
drug concentration. Error bars show SDs of data from the 30 individual cells.
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monotonic elevation that is fundamentally different from
the pulsing mode triggered by low damage.
To further confirm the role of Mdm2 in regulating the
bimodal p53 dynamics, we attenuated Mdm2 activity in
U-2 OS cells by using either RNA interference (RNAi)
knockdown or nutlin-3, a small-molecule inhibitor of
Mdm2 [16], and compared the resulting p53 dynamics
and cell fate with those after treatment of 1 μmol/l
etoposide alone (low DNA damage). Mdm2 knockdown
efficiencies were generally greater than 90%, and Mdm2
knockdown alone (without etoposide) increased p53 to a
level similar to that seen with 1 μmol/l etoposide aloneFigure 3 Regulation of bimodal p53 dynamics by Mdm2 expression. (
by western blot analysis for U-2 OS cells treated with 100 and 1 μmol/l eto
p53 expression levels with the indicated RNA interference (RNAi) treatment
etoposide; −: without etoposide. (c) Distribution of the four response phen
RNA), control siRNA, Mdm2 siRNA, and 10 μmol/l nutlin-3, in combination w
analyzed for each treatment ranged from 69 to 99. Error bars show standar
quantitative (q)PCR analysis of Mdm2 transcript level at 1 μmol/l (filled colu
standard deviations of data from three independent experiments.(Figure 3b). Approximately 70% of U-2 OS cells under
Mdm2 knockdown alone continued to divide, and less
than 10% cell death occurred in the 72 hours of the im-
aging experiment. Figure 3c compares the distributions
of the four different phenotypes, as discussed above,
after treatment with 1 μmol/l etoposide plus one of the
following four conditions: control (no siRNA), control
siRNA (control for the pro-apoptotic effect of transfec-
tion), Mdm2 knockdown, and 10 μmol/l nutlin-3. We
chose to use 10 μmol/l nutlin-3 because at this concen-
tration nutlin-3 alone induced little cell death (<4% of
U-2 OS cells died after 72 hours). Control siRNA trans-
fection slightly sensitized cells to etoposide-induced cella) Comparison of kinetics of selected proteins/protein modifications
poside, respectively. Actin served as a loading control. (b) Mdm2 and
after 0 and 24 hours of 1 μmol/l etoposide treatment. +: With
otypes for the indicated treatments: control (no small interfering (si)
ith 1 μmol/l etoposide in U-2 OS cells. The total number of cells
d deviations of data from two independent experiments. (d) Real-time
mn) and 100 μmol/l etoposide (empty columns). Error bars show
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of the phenotypic responses, with about 90% of cells
exhibiting pulsing p53 followed by cell-cycle arrest, simi-
lar to that of control cells. By contrast, Mdm2 knock-
down not only significantly upregulated p53 level
(Figure 3b) and changed the mode of p53 dynamics from
being approximately 90% oscillatory to approximately
95% monotonic increase, but also shifted cell fate from
approximately 90% cell-cycle arrest to approximately
80% cell death (Figure 3c). Similar changes in p53 dy-
namics and cell fate were also seen with etoposide plus
nutlin-3. These data strongly suggest that the bimodal
p53 dynamics are generated by differential Mdm2
upregulation modulated by DNA-damage strength, and
that the bimodal switch functions as a crucial control
over arrest versus death, as cell fate can be altered by
changing p53 dynamics.
Attenuation of Mdm2 expression at high DNA damage
could be due to reduced gene transcription or transla-
tion, or increased protein degradation. Real-time quanti-
tative PCR (qPCR) results of Mdm2 showed that the
gene-expression level of Mdm2 was largely similar under
low and high etoposide concentrations (Figure 3d).
Therefore, the distinct Mdm2 expression that we
observed at the protein level in response to variable DNA-
damage strength is not due to differential gene expression,
but possibly due to differences in translation or Mdm2 pro-
tein degradation, such as by HAUSP [17] and ATM [18].
Bimodal switch of p53 dynamics modulates the overall
transcriptional activity of p53
p53 is known to modulate cell fate through both its
transcriptional activity in the nucleus, which upregulates
downstream target genes, and its transcription-independent
pro-apoptotic activity in the cytoplasm [4,19]. To determine
whether the bimodal switch of p53 dynamics exerts controlFigure 4 p53 transcriptional activity and its effect on cell fate. (a) Gen
quantitative (q)PCR analysis in U-2 OS cells treated with 1 μmol/l (filled colu
bars show standard deviations of data from three independent experiment
western blotting analysis.over alternative cell fates by modulating the transcrip-
tional activity of p53 in upregulating distinct pro-survival
and pro-death genes, we measured, by real-time
qPCR, the gene-expression dynamics of a set of well-
characterized p53 target genes that are known to regulate
cellular response to DNA damage [20]. These target genes
include those involved in cell-cycle arrest (CDKN1A (p21)
and GADD45A), DNA repair (XPC), senescence (PML
and YPEL3) [21,22] and apoptosis (APAF1, TP53AIP1,
BAX, PUMA and NOXA). All target genes that we pro-
filed, except BAX (largely not induced), showed much
higher upregulation in response to high DNA damage
(Figure 4a), when p53 was strongly elevated in the mono-
tonic mode, irrespective of their particular functions. Of
the three most highly induced genes under monotonic
p53 in response to high DNA damage were two cell-cycle
arrest genes, that is, CDKN1A (approximately 30-fold in-
crease) and GADD45A (approximately 60-fold), and one
pro-death gene, NOXA (approximately 35-fold).
To further confirm the similar induction dynamics of
pro-survival and pro-death genes at the protein level, we
compared, by western blotting, expression levels of p21
(CDKN1A), PUMA, and BAX from U-2 OS cells treated
with 1 μmol/l (low damage) and 100 μmol/l (high dam-
age) etoposide. Expression of both the pro-survival gene
p21 and the pro-death gene PUMA were significantly in-
duced under both low and high DNA-damage levels,
whereas expression of another important pro-death
gene, BAX, was not upregulated (Figure 4b, e). These
largely agreed with the qPCR data. Hence, our results
suggest that the bimodal switch of p53 dynamics modu-
lates the transcriptional activation of pro-survival and
pro-death genes similarly, and do not differentially acti-
vate these distinct genes in a damage dose-dependent
manner. The observed bimodal switch did not appear to
regulate cell fate through the previously reportede expression of a set of well-known p53 target genes by real-time
mns) and 100 μmol/l (empty columns) etoposide, respectively. Error
s. (b) Comparison of expression of selected p53 target genes by
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and pro-apoptotic promoters [23], or through the p53-
mediated transrepression of pro-survival genes [24]. In-
stead, our data point to a mechanism in which pulsing
p53 retains a low level of p53 with target gene expression
sufficient only for inhibiting cell-cycle progression,
whereas the monotonic p53 results in strong induction of
p53 that activates sufficiently high levels of pro-death
genes to trigger cell death, superseding the concomitant
cell-cycle arrest response.
Bimodal switch of p53 dynamics modulates the p53
cytoplasmic localization, and this correlates with the
pro-apoptotic activity
The single-cell imaging data showed that although under
low etoposide dosage the cytoplasmic p53 signal was
close to that of the fluorescence background, there was
an observable increase in cytoplasmic p53 fluorescence
in response to high drug dosage, although the majority
of the activated p53 was localized in the nucleus under
both conditions. Shown in Figure 5a are representative
single-cell trajectories of p53 fluorescence in the cyto-
plasm, relative to that in the nucleus from U-2 OS cellsFigure 5 Bimodal switch of p53 dynamics modulates the p53 cytopla
p53 fluorescence in the nucleus (black line) and cytoplasm (red line) under
the indicated p53 post-translational modifications in the nucleus and cytop
for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), respectively.
used as a cytoplasmic marker and transcriptional factor II B (TFIIB) as a nuctreated with 100 μmol/l etoposide. The average p53
fluorescence in the cytoplasm was found to be about
10% of that in the nucleus. Cell-to-cell variability was
again evident, with the abundance of cytoplasmic p53
ranging from about 5% to 25% of that in the nucleus.
The single-cell data indicated that the cytoplasmic accu-
mulation of p53, which may be proportional to the cyto-
plasmic pro-apoptotic activity of p53, was modulated by
the bimodal switch of p53 dynamics as a function of
DNA-damage strength.
To determine the level of cytoplasmic p53 at the en-
semble level, we performed subcellular fractionation.
Using western blotting, we compared levels of nuclear
and cytoplasmic p53 in U-2 OS cells treated with no
drug, 1 μmol/l and 100 μmol/l etoposide, respectively
(Figure 5b). Tubulin and transcriptional factor II B
(TFIIB) were used as cytoplasmic and nuclear markers
to confirm the quality of fractionation. In contrast to
cells treated with 1 μmol/l etoposide, in which little cyto-
plasmic p53 was detected, treatment with 100 μmol/l
etoposide induced substantial accumulation of cytoplas-
mic p53 (approximately 15% of that in the nucleus). The
level of cytoplasmic p53 correlated with the differentialsmic localization. (a) Representative single-cell trajectories of average
100 μmol/l etoposide. (b) Western blotting analysis of p53 levels and
lasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated
To confirm the quality of the subcellular fractionation, tubulin was
lear marker.
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damage, where cytoplasmic p53 was low, and more than
95% cell death at high damage, where cytoplasmic p53
was significant. These data thus suggest that in addition to
the transcriptional activation of pro-death genes, bimodal
switching of p53 dynamics may also regulate cell fate by
modulating cytoplasmic accumulation of p53, which pos-
sibly correlates with its pro-apoptotic activity in the cyto-
plasm, as DNA damage increases.
Besides the induction level, activities of p53 are also
known to be regulated extensively by post-translational
modifications, such as phosphorylation and acetylation
[25,26]. Previous studies have identified several post-
translational modifications on p53 that play crucial roles
in regulating differential cell fate, such as Ser-20 phos-
phorylation by Chk1/Chk2 [27], Ser-46 phosphorylation
by HIPK2 [28], Lys-120 acetylation by Tip60 [29], and
Lys-382 acetylation by CBP/p300 [30]. To determine
whether these modifications affect the cytoplasmic accu-
mulation of p53, we measured, by western blotting, the
above four post-translational modifications in the cytoplas-
mic and nuclear fractions of p53, respectively (Figure 5b).
Whereas the extent of p53 phosphorylation at serine-20
and serine-46 was largely proportional to the expression
level of p53, irrespective of the sub-celluar localization, the
cytoplasmic fraction of p53 appeared to be preferentially
modified by acetylation at lysine-120 and lysine-382, indi-
cating that these two post-translational modifications may
potentially have important roles in regulating p53 trans-
location to cytoplasm and/or its cytoplasmic pro-apoptotic
activity.
Discussion
Our observations that p53 dynamics can switch modes
in a damage dose-dependent manner, and that cell fate
can be altered by changing the dynamic mode of p53, re-
veal a new mechanism by which the p53 pathway regu-
lates differential DNA-damage responses. By examining
both the transcriptional and non-transcriptional func-
tions of p53 at distinct damage levels, we further deter-
mined that the bimodal switch of p53 dynamics
regulates differential cell fate, mainly by modulating the
p53 induction level and pro-apoptotic activities. Under
moderate DNA damage, p53 undergoes periodic pulsing,
which might act to retain a low level of p53 induction
with low induction of pro-death genes and low cytoplas-
mic accumulation of p53. In this low damage mode, the
p53 pro-apoptotic activities are suppressed and cell-
cycle arrest dominates. In contrast, a high level of DNA
damage triggers strong monotonic elevation of p53,
which activates high levels of pro-death genes and also
promotes the cytoplasmic accumulation of p53. In this
high damage mode, the overall pro-apoptotic activities
of p53 increase, resulting in cell death and supersedingthe cell-cycle arrest response. Our data not only point to
the bimodal switch of p53 dynamics as a crucial control
over cell fate in response to variable DNA damage, but
also suggest that p53 oscillations probably function as a
suppressor through maintaining a low induction level of
p53, which suppresses its pro-apoptotic activities and
renders cell-cycle arrest that allows repair at the time of
low DNA damage.
The fact that p53 fundamentally changes its dynamic
mode, that is, switching from pulsing at low damage to
monotonic increase at high damage, poses important
new questions regarding the transitional behavior and
regulation of p53 pathway dynamics. For instance, what
is the crucial damage intensity that triggers the change
in p53 dynamics? Which p53 pathway components con-
trol this crucial damage threshold? Is the bimodal transi-
tion sharp or gradual as a function of damage level?
Answering these questions will probably require analysis
of the larger p53 pathway beyond the p53-Mdm2 nega-
tive feedback loop, so as to obtain knowledge of other
feedback structures in the p53 regulatory pathway, such
as those involved in damage sensing, p53 upregulation,
and modification. By perturbing key feedback compo-
nents connected to the central p53-Mdm2 loop and
examining how the threshold, quantitative characteris-
tics, and single-cell variability of the p53 bimodal switch
are altered, a more quantitative understanding of the bi-
modal switch will be acquired. To identify the regulatory
dependence of the bimodal switch on particular pathway
motifs, investigations that combine experimental mea-
surements and theoretical analysis of the pathway dy-
namics are clearly needed. We believe results from such
further investigations will provide important insights
into novel strategies of signaling-pathway control that
may be common in mammalian cells.
Although our results showed that differential Mdm2
upregulation was responsible for altering p53 dynamics,
the exact mechanism by which Mdm2 is differentially
regulated has not been determined. We found that
attenuation of Mdm2 expression at high DNA damage
was not due to reduction in gene transcription,
suggesting that reduction in translation or increased
protein degradation may be the potential molecular reg-
ulators. Work by Stommel and Wahl [18] showed that
auto-degradation of Mdm2 is regulated by DNA-damage
kinases, such as ATM. This suggests one possible mech-
anism for the observed attenuation in Mdm2 in response
to high DNA damage, is that as DNA damage increases,
further elevation of ATM activity triggers additional
phosphorylation of Mdm2, promoting the auto-
degradation of Mdm2 and thus reducing its protein
level. Further study will be required to determine the de-
tailed involvement of increased Mdm2 degradation in
light of the bimodal regulation of p53. Moreover, we
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p53 in the nucleus and cytoplasm as a function of DNA-
damage dose, in particular for acetylation of p53 at
lysine-120 and lysine-382. However, important questions
remain, which require further, more detailed mechanistic
study, regarding whether and how these two, or add-
itional, post-translational modifications regulatep53 con-
trol over cell fate through modulating its cytoplasmic
localization and/or its cytoplasmic pro-apoptotic activity.
Our study has shed new light on how the dual func-
tions of p53 are modulated as a function of DNA-
damage strength and differentially contribute to the
alternative phenotypic outcome, as we found alteration
in p53 dynamics mainly affects the p53 induction level
and its pro-apoptotic activities in a damage dose-
dependent manner. Although the decision between cell-
cycle arrest and cell death mediated by the bimodal p53
dynamics was mainly determined by the level of p53
pro-apoptotic activities for the system that we studied, it
is likely that the p53 pathway-mediated DNA-damage
responses vary depending on the DNA-damage stimulus
and the cell type investigated. Therefore, single-cell p53
studies for additional damage stimuli and cell types are
needed to examine potential variability in both the
bimodal switch and its regulatory effect on the dual
functions of p53.
Conclusions
In this study, using highly quantitative single-cell mi-
croscopy assays, we elucidated a novel mechanism by
which DNA damage activates a bimodal switch of p53
dynamics in a damage dose-dependent manner, subse-
quently regulating alternative phenotypic outcome of
cell-cycle arrest and cell death. Our findings not only
provide important new insights into understanding the
differential DNA-damage response mediated by p53, but
also produce quantitative new data for exploring the
transitional behavior and regulation of p53 pathway dy-
namics for cell-fate control.
Methods
p53-Venus reporter cell line
The U-2 OS and A549 cell lines were purchased from
American Type Culture Collection (ATCC, Manassas,
VA, USA) and cultured at 37°C with 5% CO2 in McCoy’s
5A or F-12K medium supplemented with 10% fetal calf
serum (FCS), 100 U/ml penicillin and 100 μg/ml strepto-
mycin. To generate fluorescent reporter cell for live-cell
imaging of p53 dynamics, we infected U-2 OS and A549
cells with lentiviruses encoding an established p53-Venus
reporter construct (consisting of wild-type p53 fused to a
yellow fluorescent protein, Venus; generous gift from Dr
Galit Lahav, Department of Systems Biology, Harvard
Medical School, USA) [9], and selected isogenic clones.Chemicals and reagents
Etoposide was purchased from Sigma-Aldrich (St. Louis,
MO, USA). siRNA for knocking down Mdm2 (#4457298)
was purchased from Ambion Inc. (Austin, TX, USA), and
the Mdm2 siRNA was used at a final concentration of 20
nmol/l for RNAi in all experiments. The non-targeting
siRNA control was On-Target plus siControl (#D-001810-
01; Dharmacon Inc., Lafayette, CO, USA). All siRNA
transfections were performed using HiPerFect (Qiagen
Inc., Valencia, CA, USA) in accordance with the manufac-
turer’s instructions. Experiments were conducted after 48
hours of gene silencing.
Western blotting analysis
Cell lysates were obtained using LDS sample buffer
(NuPAGE; Invitrogen Corp., Carlsbad, CA, USA). Pro-
teins were resolved on Tris-glycine gels and transferred
onto PVDF membranes. Blots were probed with com-
mercial primary antibodies and enhanced chemilumines-
cence detection using (ECL-Plus; Amersham Biosciences
Inc., Piscataway, NJ, USA). Antibodies used were: PARP1
(#9542), p21 (#2947), Puma (#4976), TFIIB (#4169),
phospho-p53 (Ser20) (#9287), phospho-p53 (Ser46)
(#2521) and acetyl-p53 (Lys382) (all Cell Signaling Tech-
nology/(Danvers, MA, USA); acetyl-p53 (Lys120; #BAM-
71-131-EX; Cosmo Bio, Yokohama, Japan); p53 (#sc-126),
Mdm2 (#sc-965) and Bax (#sc-493) (all from Santa Cruz
Biotechnology, Santa Cruz, CA, USA); phospho-histone
H2A.X (#06-570; Millipore Corp., Billerica, MA, USA).
Anti-actin (#A5316; (Sigma-Aldrich) and anti-tubulin
(#2148; Cell Signaling Technology) were used as loading
controls.
Real-time quantitative PCR
Total cellular RNA was isolated from U-2 OS cells
(RNeasy Mini Kit; Qiagen) in accordance with the man-
ufacturer’s instructions. A high-capacity cDNA reverse
transcription kit (Applied Biosystems, Foster City, CA,
USA) was used to reverse-transcribe RNA into cDNA,
and a SYBR Green system (Fast SYBR Green Master Mix;
Applied Biosystems) was used for DNA amplification on a
PCR system (7500 Fast Real-Time PCR System; Applied
Biosystems). The data were analyzed by Sequence Detec-
tion Systems Software (version 2.3). For the primer se-
quences for the respective genes, see Additional file 1:
Table S1.
Subcellular fractionation
U-2 OS cells were treated with trypsin, rinsed twice
with PBS, and then lysed at 4°C with isotonic buffer
(10 mmol/l Tris HCl, pH 7.5, 2 mmol/l MgCl2, 3 mmol/l
CaCl2, 3 mol/l sucrose) supplemented with 1 mmol/
ldithiothreitol (DTT) and protease inhibitor cocktail (set
III; Calbiochem, San Diego, CA, USA). Lysis buffer was
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tergent (IGEPAL CA-630; Rhodia, La Défense, France)
was then added to a final concentration of 0.03 to 0.05%,
and sample was immediately separated by centrifugation
for 30 seconds at 11,000 g and 4°C. The resulting super-
natant was taken as the cytoplasmic fraction. The pellet
was then rinsed twice with 100 μl isotonic buffer, and
taken as the nuclear fraction for western blot analysis.
Time-lapse microscopy and image analysis
Cells were plated in 35 mm imaging dishes (μ-dish; ibidi,
Planegg, Germany) and cultured in phenol red-free CO2-
independent medium (Invitrogen) supplemented with
10% FCS, 100 U/ml penicillin, and 100 μl streptomycin.
Cell images were acquired with an inverted microscope
(TE2000-PFS; Nikon, Tokyo, Japan) enclosed in a humidi-
fied chamber maintained at 37°C. Cells were imaged every
10 minutes using a motorized stage and a ×20 objective.
For data plotted in the cumulative survival curves and
the phenotype distributions, we viewed and analyzed the
images manually by eye, using MetaMorph software
(Molecular Dynamics Inc., Sunnyvale, CA, USA). In the
phase-contrast images, we scored by morphological
tracking the following: interphase (by flat morphology),
entry into mitosis (by cell rounding), cell division (by re-
spreading and splitting), cell-cycle arrest (by absence of
cell division for 72 hours) and cell death (by blebbing
followed by cell lysis). For quantifying the single-cell p53
traces, we used an automatic cell-tracking program that
we developed using MatLab. The program consists of
image-analysis procedures that sequentially segment the
individual cells, track them in time, identify the nucleus,
and measure the p53 fluorescence intensity in the
nucleus and cytoplasm, respectively. Based on the quan-
tified p53 fluorescent trajectories, we classified the
dynamic mode of nuclear p53 manually by eye. We cate-
gorized as ‘oscillatory’ any single-cell p53 signals in the
nucleus that exhibited periodic fluctuations in intensity
between a high fluorescent state and a low state near
background fluorescence. We defined a nuclear p53 sig-
nal that monotonically rose to and sustained at a high
fluorescence level as ‘monotonic increase’. Most (ap-
proximately 95%) of the p53 trajectories had obvious
features that could be unambiguously categorized into
the two distinct modes. For the 5% of trajectories that
had ambiguous features (mostly occurring at the inter-
mediate DNA damage level), we discarded these trajec-
tories from further analysis.Additional file
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